Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07608679
Starting soon Not applicable

Estimation of the Prevalence of Microcirculatory Dysfunction in Uremic Cardiopathy Among Dialysis Patients

NCT07608679 · tracked via the Priya Life Science France tracker
Sponsor
Centre Hospitalier Departemental Vendee
Phase
Not applicable
Started
2027-09
Last updated
2026-05-27

Condition(s) studied

Hemodyalysis

Investigational drug(s) / intervention(s)

Transthoracic ultrasound at restCardiological stress testCoronary angiography

Transthoracic ultrasound at rest: Transthoracic ultrasound at rest

Cardiological stress test: Left to the discretion of the centre: dobutamine echocardiography or myocardial scintigraphy.

Coronary angiography: Even even if the stress test comes back normal (these tests appear to be less effective at diagnosing microcirculatory abnormalities)

Study summary

Patients with end-stage renal disease have a high burden of cardiovascular mortality, yet ischemic heart disease is often asymptomatic and difficult to diagnose in this population. Recent data suggest that microvascular coronary dysfunction may contribute significantly to myocardial ischemia in dialysis patients, but its true prevalence remains unknown. This study aims to evaluate microcirculatory coronary impairment in hemodialysis patients using invasive coronary angiography with measurement of coronary flow reserve (CFR), index of microcirculatory resistance (IMR). The study will also describe the clinical and biological characteristics associated with microvascular dysfunction in this population, in order to better understand the mechanisms of uremic cardiomyopathy and improve cardiovascular risk stratification.

Eligibility

Sex
ALL
Min age
18 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria: * Age ≥ 18 years * Patients who have been on haemodialysis for at least 6 months * Elevated troponin levels \> 40 ng/L in a sample taken whilst the patient was in a stable condition, dated within the last 3 months * Patients capable of understanding the protocol and who have given their written informed consent to participate in the research * Patients registered with the National Health Service or eligible for it Exclusion Criteria: * Age \> 90 years * Patient undergoing daily home haemodialysis * Symptomatic stage 3 or 4 peripheral arterial disease * Severe hypertrophic cardiomyopathy (genetic or amyloid) * Severe valvular heart disease leading to left ventricular remodelling (surgically contraindicated severe aortic stenosis, severe mitral regurgitation, severe aortic regurgitation) * Hospitalisation for decompensation/acute heart failure within the last month * Acute coronary syndrome and any coronary artery disease requiring angioplasty and/or stent implantation within the last 3 months * Contraindication to METHERGIN and DOBUTAMINE * Patients participating in another clinical research protocol that may affect the research objectives * Patients already included in the study * Patients under guardianship, curatorship or deprived of their liberty * Patients under an activated future protection order * Patients under family authorisation * Patient under judicial protection * Pregnant patient

Primary outcome measure(s)

  • Percentage of patients with microcirculatory heart disease (i.e. microvascular dysfunction or microvascular vasospasm) identified during coronary angiography — Cardiac examinations to be carried out within 8 to 10 weeks of enrolment

Trial sites (1)

FacilityCityRegionStatus
Centre Hospitalier Départemental Vendée La Roche-sur-Yon France

More Centre Hospitalier Departemental Vendee trials in France

Prospective Study in Laser Treatment of Pilonidal Cysts Recruiting
Bedside Spirometry for Acute Lung Injury Starting soon
Evaluation of Omentopexy on Gastro-oesophageal Reflux Following Sleeve Gastrectomy Recruiting
Impact of Foot Reflexology on Nausea After Obesity Surgery Recruiting
Radiofrequency Ablation vs Doppler-guided Haemorrhoidal Artery Ligation in the Treatment of Haemorrhoidal Disease Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07608679 on ClinicalTrials.gov ↗ ← All trials in France